COVID-19 and cancer: what we know so far

Sidaway, Peter

doi:10.1038/s41571-020-0366-2

Cited by 90 publications

(90 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Wuhan studies report that the incidence of cancer is higher in COVID-19 patients than in the general population [33,34]. However, definitive conclusions on this issue are hampered by the small sample size, the retrospective nature of most studies, the limited follow-up duration, and the heterogeneity of the disease and treatment strategies [35,36].…”

Section: Discussionmentioning

confidence: 99%

Risk factors associated with mortality in hospitalized patients with SARS-CoV-2 infection. A prospective, longitudinal, unicenter study in Reus, Spain

Iftimie

López‐Azcona

Vicente-Miralles

et al. 2020

Preprint

View full text Add to dashboard Cite

20Spain is one of the countries that has suffered the most from the impact of severe acute 21 respiratory syndrome coronavirus 2 (SARS-CoV-2), the strain that causes coronavirus disease 22 2019 (COVID-19). However, there is a lack of information on the characteristics of this disease in 23 the Spanish population. The objective of this study has been to characterize our patients from 24 an epidemiological point of view and to identify the risk factors associated with mortality in our 25 geographical area. We performed a prospective, longitudinal study on 188 hospitalized cases of 26 SARS-Cov-2 infection in Hospital Universitari de Sant Joan, in Reus, Spain, admitted between 27 15 th March 2020 and 30 th April 2020. We recorded demographic data, signs and symptoms and 28 comorbidities. We also calculated the Charlson and McCabe indices. A total of 43 deaths 29 occurred during the study period. Deceased patients were older than the survivors (77.7 ± 13.1 30 vs. 62.8 ± 18.4 years; p < 0.001). Logistic regression analyses showed that fever, pneumonia, 31 acute respiratory distress syndrome, diabetes mellitus and cancer were the variables that 32 showed independent and statistically significant associations with mortality. The Charlson index 33 was more efficient than the McCabe index in discriminating between deceased and survivors. 34 This is one of the first studies to describe the factors associated with mortality in patients 35 infected with SARS-CoV-2 in Spain, and one of the few in the Mediterranean area. We identified 36 the main factors independently associated with mortality in our population. Further studies in 37 are needed to complete and confirm our findings. 38 39 40 41

show abstract

Section: Discussionmentioning

confidence: 99%

Risk factors associated with mortality in hospitalized patients with SARS-CoV-2 infection. A prospective, longitudinal, unicenter study in Reus, Spain

Iftimie

López‐Azcona

Vicente-Miralles

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…It has spread rapidly and was declared a global pandemic by the World Health Organization on March 11, 2020 [2]. High-risk patients, including those with advanced cancer, can experience severe symptoms including pneumonia, severe acute respiratory syndrome, and renal failure [1,3]. Mortality rates among patients with ad-vanced cancer have been estimated to be up to three times higher than among the general population [4].…”

Section: Introductionmentioning

confidence: 99%

Palliative care provision at a tertiary cancer center during a global pandemic

Hannon

Mak

Al-Awamer

et al. 2020

Support Care Cancer

View full text Add to dashboard Cite

COVID-19 was first reported in Wuhan, China, in December 2019; it rapidly spread around the world and was declared a global pandemic by the World Health Organization in March 2020. The palliative care program at the Princess Margaret Cancer Centre, Toronto, Canada, provides comprehensive care to patients with advanced cancer and their families, through services including an acute palliative care unit, an inpatient consultation service, and an ambulatory palliative care clinic. In the face of a global pandemic, palliative care teams are uniquely placed to support patients with cancer who also have COVID-19. This may include managing severe symptoms such as dyspnea and agitation, as well as guiding advance care planning and goals of care conversations. In tandem, there is a need for palliative care teams to continue to provide care to patients with advanced cancer who are COVID-negative but who are at higher risk of infection and adverse outcomes related to COVID-19. This paper highlights the unique challenges faced by a palliative care team in terms of scaling up services in response to a global pandemic while simultaneously providing ongoing support to their patients with advanced cancer at a tertiary cancer center.

show abstract

“…[3][4][5] Besides, patients with cancer patients are more susceptible to infections due to overall poor health status and systemic immunosuppressive states, which has attracted increasing attention from clinicians. [6][7][8][9][10] Currently, a key question in oncology practice amidst the COVID-19 pandemic is whether anti-cancer therapy affects COVID-19 severity and mortality.…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis

Wang

Huang

2020

OncoImmunology

View full text Add to dashboard Cite

Background: This study was designed to investigate whether COVID-19 patients with recently received immunotherapy or other anti-cancer treatments had more severe symptoms and higher mortality. Methods: A literature search was performed using the electronic platforms to obtain relevant research studies published up to June 28, 2020. Odds ratio (OR) and 95% confidence intervals (CI) of research endpoints in each study were calculated and merged. Statistical analyses were performed with Stata 12.0 (Stata Corp LP, College Station, TX). Results: A total of 17 studies comprising 3581 cancer patients with COVID-19 were included in this metaanalysis. SARS-CoV-2-infected cancer patients who recently received anti-cancer treatment did not observe a higher risk of exacerbation and mortality (All p-value >0.05). We also found that surgery, targeted therapy, chemotherapy, immunotherapy, and radiotherapy were not associated with increased risk of exacerbation and mortality (All p-value >0.05). Chemotherapy within 28 d increased the risk of death events (OR 1.45, 95% CI 1.10-1.91, P = .008, p-value = 0.015 for test of interaction), and immunotherapy within 90 d increased the risk of exacerbation (OR 2.53,95%1.30-4.91, P = .006, p-value = 0.170 for test of interaction). Conclusion: Cancer patients recently under anti-cancer treatment before diagnosed with COVID-19, including surgery, targeted therapy, immunotherapy, and radiotherapy, were not associated with increased risk of exacerbation and mortality. Chemotherapy within 28 d increased the risk of mortality, and chemotherapy was not associated with increased risk of severe COVID-19. The role of anti-cancer therapy in cancer patients with COVID-19 still needs further exploration, especially chemotherapy and immunotherapy.

show abstract

COVID-19 and cancer: what we know so far

Cited by 90 publications

References 3 publications

Risk factors associated with mortality in hospitalized patients with SARS-CoV-2 infection. A prospective, longitudinal, unicenter study in Reus, Spain

Risk factors associated with mortality in hospitalized patients with SARS-CoV-2 infection. A prospective, longitudinal, unicenter study in Reus, Spain

Palliative care provision at a tertiary cancer center during a global pandemic

Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis

Contact Info

Product

Resources

About